Mast cells selectively target large cholangiocytes during biliary injury via H2HR-mediated cAMP/pERK1/2 signaling

Bile ducts are heterogenous in structure and function, and primary sclerosing cholangitis (PSC) damages specific bile ducts leading to ductular reaction (DR), mast cell (MC) infiltration, increased histamine release, inflammation, and fibrosis. Bile duct ligation (BDL) induces large duct damage via cyclic adenosine monophosphate (cAMP)/extracellular signal-related protein kinase (ERK) signaling, and large cholangiocytes express H2 histamine receptor (H2HR). We evaluated how MCs interact with large cholangiocytes during cholestasis. Male wild-type (WT) and MC-deficient (Kit(W-sh)) mice 10-12 weeks of age were subjected to BDL for 7 days. Select Kit(W-sh) mice were injected with MCs pretreated with control or H2HR antagonist (ranitidine, 25 mu m, 48 h) via tail vein injection. In vitro, MC migration toward small mouse cholangiocytes (SMCCs) and large mouse cholangiocytes (LMCCs) treated with lipopolysaccharide or histamine (+/- ranitidine) was measured. LMCCs were stimulated with MC supernatants pretreated with control, alpha-methyl-dl-histidine (to block histamine release), or ranitidine. Liver damage, large duct DR/senescence, inflammation, fibrosis, and cAMP/ERK immunoreactivity increased in BDL WT and Kit(W-sh)+MC mice but decreased in BDL Kit(W-sh) and Kit(W-sh)+MC-H2HR mice. In vitro, MCs migrate toward damaged LMCCs (but not SMCCs) blocked by inhibition of H2HR. Loss of MC histamine or MC-H2HR decreases LMCC proliferation, senescence, H2HR, and cAMP/ERK levels. Human PSC livers have increased MC number found near DR, senescent ducts, and H2HR-positive ducts. Conclusion: Infiltrating MCs preferentially interact with large ducts via H2HR signaling promoting biliary and liver damage. Mediation of MCs may be a therapeutic strategy for PSC.

Automated summary

Bile ducts, being heterogeneous in structure and function, are damaged in primary sclerosing cholangitis (PSC), leading to various pathological changes. Mast cells (MCs) interact with large cholangiocytes during cholestasis, promoting biliary and liver damage. This finding has important implications for the treatment of PSC.